Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials (Q28084309)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials	scientific article

Statements

scholarly article

1 reference

9 references

13 March 2019

23 March 2019

17 June 2019

30 June 2019

4 August 2019

17 September 2019

28 September 2019

14 November 2020

17 December 2020

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials (English)

1 reference

rheumatoid arthritis

8 references

13 March 2019

23 March 2019

17 June 2019

30 June 2019

4 August 2019

17 September 2019

28 September 2019

14 November 2020

infectious disease

8 references

13 March 2019

23 March 2019

17 June 2019

30 June 2019

4 August 2019

17 September 2019

28 September 2019

14 November 2020

1 reference

4 August 2019

heterocyclic compound

1 reference

17 September 2019

1 reference

28 September 2019

disease-modifying antirheumatic drug

1 reference

14 November 2020

1 reference

17 December 2020

1 reference

17 December 2020

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

object named as

Vibeke Strand

1 reference

author name string

Sima Ahadieh

2

1 reference

Jonathan French

3

1 reference

Jamie Geier

4

1 reference

Sriram Krishnaswami

5

1 reference

Sujatha Menon

6

1 reference

Tina Checchio

7

1 reference

Thomas G. Tensfeldt

8

1 reference

Elaine Hoffman

9

1 reference

Richard Riese

10

1 reference

Mary Boy

11

1 reference

Juan J. Gómez-Reino

12

1 reference

language of work or name

1 reference

publication date

15 December 2015

10 references

13 March 2019

23 March 2019

17 June 2019

30 June 2019

4 August 2019

17 September 2019

28 September 2019

14 November 2020

17 December 2020

Arthritis Research and Therapy

10 references

13 March 2019

23 March 2019

17 June 2019

30 June 2019

4 August 2019

17 September 2019

28 September 2019

14 November 2020

17 December 2020

17

1 reference

362

1 reference

copyright license

Creative Commons Attribution 4.0 International

9 references

Europe PubMed Central

13 March 2019

Europe PubMed Central

23 March 2019

Europe PubMed Central

17 June 2019

Europe PubMed Central

30 June 2019

Europe PubMed Central

4 August 2019

Europe PubMed Central

17 September 2019

Europe PubMed Central

28 September 2019

Europe PubMed Central

14 November 2020

Europe PubMed Central

17 December 2020

copyright status

0 references

on focus list of Wikimedia project

0 references

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4704538

20 March 2017

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4704538

20 March 2017

Statistical aspects of the analysis of data from retrospective studies of disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4704538

20 March 2017

Quantifying heterogeneity in a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4704538

20 March 2017

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4704538

20 March 2017

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4704538

20 March 2017

Meta-analysis in clinical trials

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4704538

20 March 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4704538

29 September 2017

Rheumatoid arthritis: biological drugs and risk of infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4704538

29 September 2017

Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4704538

29 September 2017

Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4704538

29 September 2017

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4704538

29 September 2017

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4704538

29 September 2017

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4704538

29 September 2017

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4704538

29 September 2017

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4704538

29 September 2017

Targeting the Jak/STAT pathway for immunosuppression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4704538

29 September 2017

The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials

1 reference

https://api.crossref.org/works/10.1186%2FS13075-015-0880-2

21 January 2018

Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1186%2FS13075-015-0880-2

21 January 2018

High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1186%2FS13075-015-0880-2

21 January 2018

Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1186%2FS13075-015-0880-2

21 January 2018

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1186%2FS13075-015-0880-2

21 January 2018

Tofacitinib versus methotrexate in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26669566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26669566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/26669566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26669566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S13075-015-0880-2

0 references

Dimensions Publication ID

0 references

PMC publication ID

1 reference

PubMed publication ID

1 reference

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28084309&oldid=2177475956"